Metabolomics for Informing Adverse Outcome Pathways: Androgen Receptor Activation and the Pharmaceutical Spironolactone
Resources
1 resource available
-
Davis et al. 2017_Input Files.xlsx
APPLICATION/VND.OPENXMLFORMATS-OFFICEDOCUMENT.SPREADSHEETML.SHEET
Complete Metadata
| accessLevel | public |
|---|---|
| bureauCode |
[
"020:00"
]
|
| contactPoint |
{
"fn": "Drew Ekman",
"hasEmail": "mailto:ekman.drew@epa.gov"
}
|
| describedBy | https://pasteur.epa.gov/uploads/10.23719/1378557/documents/Data%20Dictionary%20for%20Davis%20et%20al.%202017_Input%20File.docx |
| describedByType | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| description | Metabolite Input Files for Determining Biochemical Pathways Impacted by Spironolactone Exposures of Fathead Minnows (Pimephales promelas) Using the Mummichog Software package. This dataset is associated with the following publication: Davis, J., D. Skelton, D. Ekman, C. LaLone, G. Ankley, G. Ankley, J. Cavallin, D. Villeneuve, and T. Collette. Metabolomics for Informing Adverse Outcome Pathways: Androgen Receptor Activation and the Pharmaceutical Spironolactone. AQUATIC TOXICOLOGY. Elsevier Science Ltd, New York, NY, USA, 184(0): 103-115, (2017). |
| distribution |
[
{
"title": "Davis et al. 2017_Input Files.xlsx",
"mediaType": "application/vnd.openxmlformats-officedocument.spreadsheetml.sheet",
"downloadURL": "https://pasteur.epa.gov/uploads/10.23719/1378557/Davis%20et%20al.%202017_Input%20Files.xlsx"
}
]
|
| identifier | https://doi.org/10.23719/1378557 |
| keyword |
[
"AOPs",
"Mummichog",
"mass spectrometry",
"metabolomics",
"spironolactone"
]
|
| license | https://pasteur.epa.gov/license/sciencehub-license.html |
| modified | 2017-08-14 |
| programCode |
[
"020:095"
]
|
| publisher |
{
"name": "U.S. EPA Office of Research and Development (ORD)",
"subOrganizationOf": {
"name": "U.S. Environmental Protection Agency",
"subOrganizationOf": {
"name": "U.S. Government"
}
}
}
|
| references |
[
"https://doi.org/10.1016/j.aquatox.2017.01.001"
]
|
| rights |
null
|
| title | Metabolomics for Informing Adverse Outcome Pathways: Androgen Receptor Activation and the Pharmaceutical Spironolactone |